Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

This Predicts When MDS Will Advance to AML

Leuk Lymphoma; ePub 2017 Jan 13; Guo, et al

Publish date:: January 18, 2017

Small non-coding RNA (sRNA) biomarkers predicted when myelodysplastic syndromes (MDS) were likely to advance to acute myeloid leukemia (AML) in a recent study.

Investigators conducted sRNA sequencing on 1) MDS patients who either did or did not progress to AML, and 2) AML patients with myelodysplasia-related changes. Among the results:

5 miRNAs differentiated between MDS patients who did and did not progress.
This included 3 members of the miR-181 family, as well as differential patterns of miRNA isoforms and tDRs.

Citation:

Guo Y, Strickland S, Mohan S, et al. MicroRNAs and tRNA-derived fragments predict the transformation of myelodysplastic syndromes to acute myeloid leukemia. [Published online ahead of print January 13, 2017]. Leuk Lymphoma. doi:10.1080/10428194.2016.1272680.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in AML

Beat AML: Precision medicine strategy feasible, superior to SOC for AML,

Survey quantifies COVID-19’s impact on oncology,

Combo drug improves survival in older patients with high-risk/secondary AML,

Venetoclax plus LDAC tops LDAC alone in AML,

Azacitidine plus enasidenib improves response, but not survival, in mIDH2 AML,